GLP-1 and Hyperoxia for Organ Protection in Heart Surgery
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Patients undergoing open heart surgery are at risk of suffering damage to the heart, brain
and kidneys.
This study is designed as a 2-by-2 randomized clinical trial with the purpose of
investigating the organ protective effects of the glucagon-like-peptide-1 (GLP-1) agonist
Exenatide versus placebo and restrictive versus liberal oxygenation during weaning from
cardio-pulmonary bypass.